Perioperative Management of Patients with Atrial Fibrillation Receiving a Direct Oral Anticoagulant

JAMA Internal Medicine

Volumn 179, Issue 11, 2019, Pages 1469-1478

  Douketis, James D ^a   Spyropoulos, Alex C ^b   Duncan, Joanne ^a   Carrier, Marc ^c   Le Gal, Gregoire ^d   Tafur, Alfonso J ^e   Vanassche, Thomas ^f   Verhamme, Peter ^f   Shivakumar, Sudeep ^g   Gross, Peter L ^a   Lee, Agnes Y Y ^h   Yeo, Erik ⁱ   Solymoss, Susan ^j   Kassis, Jeannine ^k   Le Templier, Geneviève ^l   Kowalski, Stephen ^m   Blostein, Mark ⁿ   Shah, Vinay ^o   Mackay, Elizabeth ^p   Wu, Cynthia ^q   Clark, Nathan P ^r   Bates, Shannon M ^a   Spencer, Frederick A ^a   Arnaoutoglou, Eleni ^s   Coppens, Michiel ^t   Arnold, Donald M ^a   Caprini, Joseph A ^e   Li, Na ^a   Moffat, Karen A ^u   Syed, Summer ^u   Schulman, Sam ^a,v   more..

^a MCMASTER UNIVERSITY   (Canada)

^b LENOX HILL HOSPITAL   (United States)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d INSTITUT DU SAVOIR MONTFORT   (Canada)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g DALHOUSIE UNIVERSITY   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j MONTREAL GENERAL HOSPITAL   (Canada)

^k UNIVERSITÉ DE MONTRÉAL   (Canada)

^l CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^m UNIVERSITY OF MANITOBA   (Canada)

ⁿ MCGILL UNIVERSITY   (Canada)

^o HENRY FORD HOSPITAL   (United States)

^p UNIVERSITY OF CALGARY   (Canada)

^q UNIVERSITY OF ALBERTA   (Canada)

^r KAISER PERMANENTE   (United States)

^s UNIVERSITY OF THESSALY   (Greece)

^t ACADEMIC MEDICAL CENTER   (Netherlands)

^u MCMASTER UNIVERSITY   (Canada)

^v I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; RIVAROXABAN;

AGED; ANTICOAGULANT THERAPY; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CANADA; CONTROLLED STUDY; CREATININE CLEARANCE; ELECTIVE SURGERY; EUROPE; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SAFETY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT INTERRUPTION; UNITED STATES;

EID: 85071247441     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2019.2431     Document Type: Article

References (36)

1. Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost. 2016; 14 (5): 875-885. doi: 10.1111/jth.13305 26988871
2. Zulkifly H, Lip GYH, Lane DA. Epidemiology of atrial fibrillation. Int J Clin Pract. 2018; 72 (3): e13070. doi: 10.1111/ijcp.13070 29493854
3. Healey JS, Eikelboom J, Douketis J,; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial [published correction appears in Circulation. 2012;126(10):e160]. Circulation. 2012; 126 (3): 343-348. doi: 10.1161/CIRCULATIONAHA.111.090464 22700854
4. Spyropoulos AC, Douketis JD. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood. 2012; 120 (15): 2954-2962. doi: 10.1182/blood-2012-06-415943 22932800
5. Dunn AS, Spyropoulos AC, Turpie AG. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost. 2007; 5 (11): 2211-2218. doi: 10.1111/j.1538-7836.2007.02729.x 17697140
6. Douketis JD, Healey JS, Brueckmann M, Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost. 2015; 113 (3): 625-632. doi: 10.1160/TH14-04-0305 25472710
7. Douketis JD, Spyropoulos AC, Kaatz S,; BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med. 2015; 373 (9): 823-833. doi: 10.1056/NEJMoa1501035 26095867
8. Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: reply. J Thromb Haemost. 2016; 14 (12): 2559-2561. doi: 10.1111/jth.13513 27662099
9. Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. J Thromb Haemost. 2016; 14 (12): 2556-2559. doi: 10.1111/jth.13505 27622661
10. Garcia D, Alexander JH, Wallentin L, Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood. 2014; 124 (25): 3692-3698. doi: 10.1182/blood-2014-08-595496 25320240
11. Sherwood MW, Douketis JD, Patel MR,; ROCKET AF Investigators. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation. 2014; 129 (18): 1850-1859. doi: 10.1161/CIRCULATIONAHA.113.005754 24552831
12. Beyer-Westendorf J, Gelbricht V, Förster K, Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J. 2014; 35 (28): 1888-1896. doi: 10.1093/eurheartj/eht557 24394381
13. Godier A, Dincq AS, Martin AC, Predictors of pre-procedural concentrations of direct oral anticoagulants: a prospective multicentre study. Eur Heart J. 2017; 38 (31): 2431-2439. doi: 10.1093/eurheartj/ehx403 28821169
14. Schulman S, Carrier M, Lee AY,; Periop Dabigatran Study Group. Perioperative management of dabigatran: a prospective cohort study. Circulation. 2015; 132 (3): 167-173. doi: 10.1161/CIRCULATIONAHA.115.015688 25966905
15. Faraoni D, Samama CM, Ranucci M, Dietrich W, Levy JH. Perioperative management of patients receiving new oral anticoagulants: an international survey. Clin Lab Med. 2014; 34 (3): 637-654. doi: 10.1016/j.cll.2014.06.006 25168948
16. Narouze S, Benzon HT, Provenzano DA, Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2015; 40 (3): 182-212. doi: 10.1097/AAP.0000000000000223 25899949
17. Raval AN, Cigarroa JE, Chung MK,; American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation. 2017; 135 (10): e604-e633. doi: 10.1161/CIR.0000000000000477 28167634
18. Albaladejo P, Bonhomme F, Blais N,; French Working Group on Perioperative Hemostasis (GIHP). Management of direct oral anticoagulants in patients undergoing elective surgeries and invasive procedures: updated guidelines from the French Working Group on Perioperative Hemostasis (GIHP)-September 2015. Anaesth Crit Care Pain Med. 2017; 36 (1): 73-76. doi: 10.1016/j.accpm.2016.09.002 27659969
19. Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med. 2018; 43 (3): 263-309. doi: 10.1097/AAP.0000000000000763 29561531
20. Steffel J, Verhamme P, Potpara TS,; ESC Scientific Document Group. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39 (16): 1330-1393. doi: 10.1093/eurheartj/ehy136 29562325
21. Siegal D, Yudin J, Kaatz S, Douketis JD, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012; 126 (13): 1630-1639. doi: 10.1161/CIRCULATIONAHA.112.105221 22912386
22. Douketis JD, Spyropoulos AC, Anderson JM, The perioperative anticoagulant use for surgery evaluation (PAUSE) study for patients on a direct oral anticoagulant who need an elective surgery or procedure: design and rationale. Thromb Haemost. 2017; 117 (12): 2415-2424. doi: 10.1160/TH17-08-0553 29212129
23. Vandenbroucke JP, von Elm E, Altman DG,; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology. 2007; 18 (6): 805-835. doi: 10.1097/EDE.0b013e3181577511 18049195
24. Euser AM, Zoccali C, Jager KJ, Dekker FW. Cohort studies: prospective versus retrospective. Nephron Clin Pract. 2009; 113 (3): c214-c217. doi: 10.1159/000235241 19690438
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16 (1): 31-41. doi: 10.1159/000180580 1244564
26. Doherty JU, Gluckman TJ, Hucker WJ, 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol. 2017; 69 (7): 871-898. doi: 10.1016/j.jacc.2016.11.024 28081965
27. Douketis JD, Spyropoulos AC, Spencer FA, Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. [published correction appears in Chest. 2012;141(4):1129]. Chest. 2012; 141 (2)(suppl): e326S-e350S. doi: 10.1378/chest.11-2298 22315266
28. Schulman S, Angerås U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost. 2010; 8 (1): 202-204. doi: 10.1111/j.1538-7836.2009.03678.x 19878532
29. Spyropoulos AC, Douketis JD, Gerotziafas G, Kaatz S, Ortel TL, Schulman S; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost. 2012; 10 (4): 692-694. doi: 10.1111/j.1538-7836.2012.04630.x 22934291
30. Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest. 2017; 151 (1): 127-138. doi: 10.1016/j.chest.2016.08.1462 27637548
31. Tripodi A, Padovan L, Veena C, Scalambrino E, Testa S, Peyvandi F. How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res. 2015; 135 (6): 1186-1190. doi: 10.1016/j.thromres.2015.03.032 25895845
32. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003; 163 (8): 901-908. doi: 10.1001/archinte.163.8.901 12719198
33. Wallis S. Binomial confidence intervals and contingency tests: mathematical fundamentals and the evaluation of alternative methods. J Quant Linguist. 2013; 20 (3): 178-208. doi: 10.1080/09296174.2013.799918
34. Clark NP, Douketis JD, Hasselblad V, Schulman S, Kindzelski AL, Ortel TL; BRIDGE Investigators. Predictors of perioperative major bleeding in patients who interrupt warfarin for an elective surgery or procedure: analysis of the BRIDGE trial. Am Heart J. 2018; 195: 108-114. doi: 10.1016/j.ahj.2017.09.015 29224638
35. Forslund T, Komen JJ, Andersen M, Improved stroke prevention in atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants. Stroke. 2018; 49 (9): 2122-2128. doi: 10.1161/STROKEAHA.118.021990 30354995
36. Clark NP, Witt DM, Davies LE, Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med. 2015; 175 (7): 1163-1168. doi: 10.1001/jamainternmed.2015.1843 26010033